ReShape Lifesciences Stock Surges 47.6% Ahead of Vyome Merger and Nasdaq Rebrand

Introduction

ReShape Lifesciences Inc. (Nasdaq: RSLS) is a United States–based medical device company focused on solutions for obesity and metabolic diseases. On August 13, 2025, shares closed at $2.9973, reflecting a 47.65% increase on a volume of 1,414,293. The company’s core offerings include the FDA-approved Lap-Band® program, the investigational ReShape Vest™ System, and the reshapecare® virtual health coaching program.

Corporate Structure

Founded in 2002 and headquartered in Eden Prairie, Minnesota, ReShape Lifesciences employs between 11 and 50 people. Its product portfolio includes minimally invasive gastric devices and a reimbursed tele-health weight-management service. The company operates a research and development center in the United States and maintains commercial partnerships to support global distribution.

Obesity treatment by Christopher Williams

Developments and News

On July 30, 2025, ReShape filed a Form 425 to solicit shareholder approval for a business combination with Vyome Therapeutics. The special meeting for this purpose was adjourned to August 7, 2025, as noted in its proxy materials. On August 11, 2025, a Form 8-K filing (Item 5.07) disclosed a change in the company’s certifying accountant. An amendment to its Schedule 13G, filed on August 13, 2025, revealed that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC, and Waqas Khatri each hold 80 shares (0.0% of the class).

Industry events in August 2025 included ReShape’s inaugural Lap-Band Surgeon Summit, held from August 1–3 in Nashville, Tennessee, which convened bariatric surgeons to discuss Lap-Band® technologies and GLP-1 adjunct therapies. A LinkedIn update indicated that shareholders confirmed all proposals necessary to complete the merger with Vyome Therapeutics, set to close on August 15, 2025. Following the merger, the combined entity will be renamed Vyome Holdings, Inc. and will trade on Nasdaq under the ticker symbol HIND. The company also announced U.S. Patent No. 12,350,179, which covers its intragastric device and is secured through at least January 2031.

Financial and Strategic Analysis

Detailed financial results are not available in the recent 8-K or Schedule 13G filings, which focus primarily on ownership and governance matters. The 47.65% price increase on August 13 indicates increased trading interest ahead of the merger with Vyome. Strategically, the transaction aims to broaden the product pipeline to include immune-inflammatory assets and leverage Vyome’s research capabilities. The Form 425 highlights efforts to link the Indian innovation corridor with U.S. markets, suggesting a focus on diversifying research and development and commercial reach. Key challenges include regulatory approvals, shareholder engagement in corporate actions, and competition from both surgical and pharmaceutical obesity treatments.

Market Position and Industry Context

ReShape competes in a growing obesity-treatment market that encompasses medical devices, pharmacotherapies, and digital health solutions. Its Lap-Band platform provides a less invasive alternative to gastric bypass and sleeve gastrectomy, while the ReShape Vest™ and virtual coaching address market demand for reversible and lifestyle-oriented therapies. With over 160 issued and pending patents, including the recent patent for the intragastric device, the company has established a significant intellectual property portfolio. The transition to Vyome Holdings positions the combined entity to compete more broadly in metabolic and immune-inflammatory indications under a unified Nasdaq listing.

tl;dr

• On August 13, 2025, RSLS shares closed at $2.9973 (+47.65%).
• The Vyome Therapeutics merger is set to take effect on August 15, 2025, with the new ticker HIND.
• A Lap-Band Surgeon Summit was held from August 1–3, 2025, in Nashville, Tennessee.
• Recent SEC filings (Form 425 on July 30; 8-K on August 11; Schedule 13G/A on August 13) addressed shareholder votes, accountant changes, and beneficial ownership.
• U.S. Patent No. 12,350,179 was granted, extending protection for the intragastric device through January 2031.